Hormonal interactions in endometrial cancer.

in Endocrine-Related Cancer
Authors:
G Emons Department of Obstetrics and Gynecology, Georg-August-Universität, Robert-Koch-Straszlig;-e 40, D-37075 Göttingen, Germany.

Search for other papers by G Emons in
Current site
Google Scholar
PubMed Close
,
G Fleckenstein Department of Obstetrics and Gynecology, Georg-August-Universität, Robert-Koch-Straszlig;-e 40, D-37075 Göttingen, Germany.

Search for other papers by G Fleckenstein in
Current site
Google Scholar
PubMed Close
,
B Hinney Department of Obstetrics and Gynecology, Georg-August-Universität, Robert-Koch-Straszlig;-e 40, D-37075 Göttingen, Germany.

Search for other papers by B Hinney in
Current site
Google Scholar
PubMed Close
,
A Huschmand Department of Obstetrics and Gynecology, Georg-August-Universität, Robert-Koch-Straszlig;-e 40, D-37075 Göttingen, Germany.

Search for other papers by A Huschmand in
Current site
Google Scholar
PubMed Close
, and
W Heyl Department of Obstetrics and Gynecology, Georg-August-Universität, Robert-Koch-Straszlig;-e 40, D-37075 Göttingen, Germany.

Search for other papers by W Heyl in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 7: Issue 4
Article Type:
Abstract
Page Range:
227–242
Online Publication Date:
Dec 2000
Free access

Sign up for journal news

Endometrial cancer (EC) is the most frequent malignant tumor of the female genital tract. Increasing evidence suggests that at least two different types of EC exist. Type I is associated with an endocrine milieu of estrogen predominance. These tumors are of endometrioid histology and develop from endometrial hyperplasia. They have a good prognosis and are sensitive to endocrine manipulation. Type II EC is not associated with a history of unopposed estrogens and develops from the atrophic endometrium of elderly women. They are of serous histology, have a poor prognosis, and do not react to endocrine manipulation. Both types of EC probably differ markedly with regard to the molecular mechanisms of malignant transformation. This article reviews reproductive and lifestyle factors modifying the risk of developing type I EC, including the use of hormonal contraceptives, hormone replacement therapy and tamoxifen. The roles of established and novel therapies for precancerous lesions and for invasive EC in the adjuvant and palliative settings are discussed.

Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.

The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.

More information is on the Reasons to publish page.

Sept 2018 onwards Past Year Past 30 Days
Full Text Views 569 286 31
PDF Downloads 336 152 11

 

  • Collapse
  • Expand
Print ISSN:
1351-0088
Online ISSN:
1479-6821
Page(s):
16
Print Publication Date:
01 Jan 2000
Online Publication Date:
Dec 2000